Another experimental Alzheimer’s drug has been shown to slow patients’ worsening conditions, researchers reported Monday. The American drug company Eli Lilly said it is seeking U.S. Food and Drug Administration (FDA) approval for the drug donanemab. If approved, it would be the second Alzheimer’s treatment for delaying the disease. Alzheimer’s affects the brain and causes memory loss and dementia. The FDA approved Leqembi, from Japanese drugmaker Eisai, earlier this month. “Finally there’s some hope, right, that we can talk about,” Lilly’s Dr. John Sims told reporters Monday at the Alzheimer’s Association International Conference in Amsterdam, the Netherlands. The drug does not cure the disease. Instead, it slows its progression by about four to seven months. But Sims noted that “it doesn’t mean you can’t have very meaningful treatments for patients.” Eli Lilly published the full results of its study of 1,700 patients in the Journal of the American Medical Association. It also presented its results at the Alzheimer’s conference.